260 related articles for article (PubMed ID: 36197958)
21. Management of chronic myeloid leukemia in 2023 - common ground and common sense.
Senapati J; Sasaki K; Issa GC; Lipton JH; Radich JP; Jabbour E; Kantarjian HM
Blood Cancer J; 2023 Apr; 13(1):58. PubMed ID: 37088793
[TBL] [Abstract][Full Text] [Related]
22. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results.
Mauro MJ; Hughes TP; Kim DW; Rea D; Cortes JE; Hochhaus A; Sasaki K; Breccia M; Talpaz M; Ottmann O; Minami H; Goh YT; DeAngelo DJ; Heinrich MC; Gómez-García de Soria V; le Coutre P; Mahon FX; Janssen JJWM; Deininger M; Shanmuganathan N; Geyer MB; Cacciatore S; Polydoros F; Agrawal N; Hoch M; Lang F
Leukemia; 2023 May; 37(5):1048-1059. PubMed ID: 36949155
[TBL] [Abstract][Full Text] [Related]
23. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2020 Jun; 95(6):691-709. PubMed ID: 32239758
[TBL] [Abstract][Full Text] [Related]
24. Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia.
Haddad FG; Issa GC; Jabbour E; Yilmaz M
Expert Opin Pharmacother; 2022 May; 23(7):751-758. PubMed ID: 35412404
[TBL] [Abstract][Full Text] [Related]
25. Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase.
Choi EJ
Blood Res; 2023 Apr; 58(S1):S29-S36. PubMed ID: 36891575
[TBL] [Abstract][Full Text] [Related]
26. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
Hochhaus A; Réa D; Boquimpani C; Minami Y; Cortes JE; Hughes TP; Apperley JF; Lomaia E; Voloshin S; Turkina A; Kim DW; Abdo A; Fogliatto LM; le Coutre P; Sasaki K; Kim DDH; Saussele S; Annunziata M; Chaudhri N; Chee L; García-Gutiérrez V; Kapoor S; Allepuz A; Quenet S; Bédoucha V; Mauro MJ
Leukemia; 2023 Mar; 37(3):617-626. PubMed ID: 36717654
[TBL] [Abstract][Full Text] [Related]
27. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
Jiang Q; Li Z; Qin Y; Li W; Xu N; Liu B; Zhang Y; Meng L; Zhu H; Du X; Chen S; Liang Y; Hu Y; Liu X; Song Y; Men L; Chen Z; Niu Q; Wang H; Lu M; Yang D; Zhai Y; Huang X
J Hematol Oncol; 2022 Aug; 15(1):113. PubMed ID: 35982483
[TBL] [Abstract][Full Text] [Related]
28. Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy.
Khadadah FM; Cerquozzi S; Olney HJ; Fraga C; Dudebout J; Xenocostas A; Finn N; Ethier V; Savoie ML; Busque L; Jamani K; Kuruvilla P; Faught C; Leber B; Kaedbey R; Assouline SE; Kim D
Leuk Res; 2023 Oct; 133():107374. PubMed ID: 37657146
[TBL] [Abstract][Full Text] [Related]
29. Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?
Padala S; Cortes J
Haematologica; 2023 Nov; 108(11):2913-2918. PubMed ID: 37102603
[TBL] [Abstract][Full Text] [Related]
30. Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes.
Hijiya N; Mauro MJ
Cancer Manag Res; 2023; 15():873-891. PubMed ID: 37641687
[TBL] [Abstract][Full Text] [Related]
31. An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors.
García-Gutiérrez V; Hernandez-Boluda JC
Expert Rev Hematol; 2022 Jun; 15(6):477-484. PubMed ID: 35583386
[TBL] [Abstract][Full Text] [Related]
32. Combination of an aurora kinase inhibitor and the ABL tyrosine kinase inhibitor asciminib against ABL inhibitor-resistant CML cells.
Okabe S; Moriyama M; Gotoh A
Med Oncol; 2024 May; 41(6):142. PubMed ID: 38714583
[TBL] [Abstract][Full Text] [Related]
33. CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1
Schneeweiss-Gleixner M; Byrgazov K; Stefanzl G; Berger D; Eisenwort G; Lucini CB; Herndlhofer S; Preuner S; Obrova K; Pusic P; Witzeneder N; Greiner G; Hoermann G; Sperr WR; Lion T; Deininger M; Valent P; Gleixner KV
EBioMedicine; 2019 Dec; 50():111-121. PubMed ID: 31761618
[TBL] [Abstract][Full Text] [Related]
34. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
35. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Réa D; Mauro MJ; Boquimpani C; Minami Y; Lomaia E; Voloshin S; Turkina A; Kim DW; Apperley JF; Abdo A; Fogliatto LM; Kim DDH; le Coutre P; Saussele S; Annunziata M; Hughes TP; Chaudhri N; Sasaki K; Chee L; García-Gutiérrez V; Cortes JE; Aimone P; Allepuz A; Quenet S; Bédoucha V; Hochhaus A
Blood; 2021 Nov; 138(21):2031-2041. PubMed ID: 34407542
[TBL] [Abstract][Full Text] [Related]
36. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia.
Luna A; Pérez-Lamas L; Boque C; Giraldo P; Xicoy B; Ruiz Nuño C; Vega MM; Alvarez-Larrán A; Salamanca A; García-Noblejas A; Vall-Llovera F; Villalon L; De Las Heras N; Ramila E; Pérez-Encinas M; Cuevas B; Perez-Lopez R; Sanchez-Guijo F; Jiménez-Velasco A; Lakhwani S; Casado LF; Rosell A; Escola A; Fernández MJ; Garcia-Hernandez C; Cervero C; Mora E; Sagüés M; Suarez-Varela S; Vélez P; Carrascosa Mastell P; Bitaube RF; Serrano L; Cortes M; Vera Goñi JA; Steegmann JL; de Soria VGG; Alonso-Dominguez JM; Araujo MC; Coll AP; Hernandez-Boluda JC; García-Gutiérrez V
Ann Hematol; 2022 Oct; 101(10):2263-2270. PubMed ID: 35997804
[TBL] [Abstract][Full Text] [Related]
37. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Syed YY; McCormack PL; Plosker GL
BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842
[TBL] [Abstract][Full Text] [Related]
38. Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing
Gleixner KV; Filik Y; Berger D; Schewzik C; Stefanzl G; Sadovnik I; Degenfeld-Schonburg L; Eisenwort G; Schneeweiss-Gleixner M; Byrgazov K; Sperr WR; Mayer J; Lion T; Valent P
Am J Cancer Res; 2021; 11(9):4470-4484. PubMed ID: 34659899
[TBL] [Abstract][Full Text] [Related]
39. Management of TKI-resistant chronic phase CML.
Hughes TP; Shanmuganathan N
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):129-137. PubMed ID: 36485117
[TBL] [Abstract][Full Text] [Related]
40. Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors.
Haddad FG; Kantarjian H
J Natl Compr Canc Netw; 2024 Feb; 22(1):. PubMed ID: 38394773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
